Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Show more

Location: 21925 W. Field Parkway, Deer Park, IL, 60010-7278, United States | Website: https://www.etonpharma.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

468M

52 Wk Range

$4.52 - $21.48

Previous Close

$17.45

Open

$17.51

Volume

164,415

Day Range

$17.31 - $18.00

Enterprise Value

473.8M

Cash

25.38M

Avg Qtr Burn

N/A

Insider Ownership

4.39%

Institutional Own.

62.48%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ZONISADE (Zonisamide) (ET-104) Details
Rare genetic disease, Neurological disorder

Approved

Update

Carbaglu® (carglumic acid tablets) Details
Hyperammonemia NAGS deficient, chronic hyperammonemia

Approved

Quarterly sales

ALKINDI® SPRINKLE (hydrocortisone) Details
Adrenocortical Insufficiency (Pediatrics)

Approved

Quarterly sales

Cysteine hydrochloride injection (generic - ANDA) Details
Additive to amino acid solutions to meet the nutritional requirements of newborn infants

Approved

Quarterly sales

EPRONTIA (Topiramate Oral Solution) (ET-101) Details
Tonic-clonic seizures / seizures / migraine

Approved

Quarterly sales

KHINDIVI™ (hydrocortisone) Oral Solution Details
Pediatric Adrenocortical Insufficiency

Approved

Quarterly sales

Approved

Quarterly sales

Biorphen® (phenylephrine HCI) Details
Hypotension (vasodilation in the setting of anesthesia)

Approved

Quarterly sales

Approved

Quarterly sales

Nitisinone Capsules Details
Tyrosinemia type 1, Rare diseases

Approved

Quarterly sales

PDUFA

Approval decision

Lamotrigine Oral Suspension (ET-105) Details
Seizures, Epilepsy, Lennox-Gastaut syndrome

Failed

Discontinued

Failed

Discontinued